[go: up one dir, main page]

PE20211218A1 - Suspensiones liquidas de paracetamol - Google Patents

Suspensiones liquidas de paracetamol

Info

Publication number
PE20211218A1
PE20211218A1 PE2021000247A PE2021000247A PE20211218A1 PE 20211218 A1 PE20211218 A1 PE 20211218A1 PE 2021000247 A PE2021000247 A PE 2021000247A PE 2021000247 A PE2021000247 A PE 2021000247A PE 20211218 A1 PE20211218 A1 PE 20211218A1
Authority
PE
Peru
Prior art keywords
suspensions
paracetamol
equal
less
liquid
Prior art date
Application number
PE2021000247A
Other languages
English (en)
Inventor
Mauro Cavinato
Karin Gerola
Original Assignee
Gsk Consumer Healthcare Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gsk Consumer Healthcare Sarl filed Critical Gsk Consumer Healthcare Sarl
Publication of PE20211218A1 publication Critical patent/PE20211218A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion se refiere a suspensiones liquidas farmaceuticas adecuadas para administracion oral. Mas especificamente, la presente invencion se refiere a suspensiones liquidas farmaceuticas que contienen paracetamol en donde las suspensiones estan formuladas con particulas de paracetamol que tienen un d50 de menor que o igual a 10 micro mol y un d90 de menor que o igual a 35 micro mol de tal manera que la decoloracion por oxidacion se reduce durante el almacenamiento prolongado. Dicha composicion esta sustancialmente libre de azucares invertidos y azucares reductores; ademas, comprende un edulcorante de alta intensidad tal como sucralosa, aspartamo, sacarina, entre otros; un edulcorante de alcohol polihidrico tal como sorbitol, manitol, xilitol, entre otros; un conservador antimicrobiano tal como metil parabeno, propil parabeno, entre otros; un agente espesante tal como goma de xantano; y un humectante tal como glicerina.
PE2021000247A 2018-08-28 2019-08-22 Suspensiones liquidas de paracetamol PE20211218A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862723561P 2018-08-28 2018-08-28
PCT/EP2019/072445 WO2020043587A1 (en) 2018-08-28 2019-08-22 Paracetamol liquid suspensions

Publications (1)

Publication Number Publication Date
PE20211218A1 true PE20211218A1 (es) 2021-07-05

Family

ID=67766153

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021000247A PE20211218A1 (es) 2018-08-28 2019-08-22 Suspensiones liquidas de paracetamol

Country Status (10)

Country Link
US (1) US11786462B2 (es)
EP (1) EP3843703B1 (es)
CN (1) CN112888427A (es)
AU (2) AU2019328411B2 (es)
BR (1) BR112021003544A2 (es)
CO (1) CO2021002721A2 (es)
MY (1) MY210511A (es)
PE (1) PE20211218A1 (es)
SG (1) SG11202101320RA (es)
WO (1) WO2020043587A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112274483A (zh) * 2020-10-28 2021-01-29 河北冀衡药业股份有限公司 一种对乙酰氨基酚混悬滴剂及其制备方法
WO2022178018A1 (en) * 2021-02-19 2022-08-25 Nevakar Injectables Inc. Liquid unit dosage forms for treatment of pain

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272137A (en) 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
CA2121435C (en) 1993-04-16 2002-01-22 Sheila M. Ratnaraj Aqueous pharmaceutical suspension and process for preparation thereof
US7101572B2 (en) * 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
US7300670B2 (en) * 2002-04-03 2007-11-27 Unilab Pharmatech, Ltd. Oral suspension formulation
DE10234784A1 (de) * 2002-07-30 2004-02-19 Günenthal GmbH Intravenös applizierbare, pharmazeutische Darreichungsform
US20060093629A1 (en) 2004-10-29 2006-05-04 Buehler Gail K Dye-free pharmaceutical suspensions and related methods
EA015336B1 (ru) 2005-06-03 2011-06-30 Элан Фарма Интернэшнл Лтд. Стабильная композиция с наночастицами ацетаминофена

Also Published As

Publication number Publication date
AU2019328411A1 (en) 2021-03-11
EP3843703A1 (en) 2021-07-07
CN112888427A (zh) 2021-06-01
EP3843703C0 (en) 2025-11-05
US20210251896A1 (en) 2021-08-19
MY210511A (en) 2025-09-28
EP3843703B1 (en) 2025-11-05
AU2019328411B2 (en) 2022-02-10
SG11202101320RA (en) 2021-03-30
AU2022202456A1 (en) 2022-05-05
BR112021003544A2 (pt) 2021-05-18
US11786462B2 (en) 2023-10-17
CO2021002721A2 (es) 2021-05-20
WO2020043587A1 (en) 2020-03-05

Similar Documents

Publication Publication Date Title
ES2584858T3 (es) Composiciones farmacéuticas acuosas que contienen complejos de borato-poliol
AR070887A1 (es) Composiciones farmaceuticas acuosas que contienen complejos de borato - poliol
ES2542728T3 (es) Composiciones farmacéuticas que tienen la biodisponibilidad deseable
CO6180448A2 (es) Gel conteniendo pirfenidona
MX2014001101A (es) Composiciones orales que contienen un ester 17-hydroxyprogesterona y metodos relacionados.
BR112012017979A2 (pt) formulações líquidas para conjugado de g-csf ação prolongada
PE20080374A1 (es) Composiciones farmaceuticas de ropinirol
PE20200698A1 (es) Gel que comprende clorhexidina
PE20010627A1 (es) Composiciones que tienen estabilidad mejorada
AR073793A1 (es) Formulacion farmaceutica liquida que contiene paracetamol. excipiente liquido
CO6361904A2 (es) Composiciones de dosis orales de liberación retardad que contienen bardoloxona-metilo (cddo-me) amorfo
PE20120584A1 (es) Preparaciones farmaceuticas transdermicas
AR077464A1 (es) Terapia de combinacion para el tratamiento de la diabetes
PE20211218A1 (es) Suspensiones liquidas de paracetamol
EA201001324A1 (ru) Гель, обладающий противовоспалительным и противоаллергическим действием
AR083879A1 (es) Analogos de aminoglicosidos antibacterianos, metodos de preparacion y uso como agentes terapeuticos
ES2405531R1 (es) Formulaciones sólidas y su uso en el mantenimiento de la salud gastrointestinal
PE20180026A1 (es) Composicion topica curativa
AR116026A1 (es) Composición para erradicar helicobacter pylori
AR093297A1 (es) Formulacion liquida que comprende un compuesto neutralizante de gm-csf
BRPI0502145A (pt) enxaguatório para prevenção e tratamento da halitose
AR094015A1 (es) Metodos para blanquear los dientes
PE20120781A1 (es) Formulacion de omeprazol farmaceutica estable para administracion oral
ES2593618T3 (es) Composición oral tópica para aliviar los síntomas de la boca seca y para el tratamiento de úlceras bucales
AR046314A1 (es) Composiciones que comprenden ciclohexilaminas y aminoadamantanos